Welcoming remarks by Dr Osborne E Nyandiva on Symposium: Cervical cancer and its prevention
Co-Presenter Dr Giama. We are happy to present to you this very crucial discussion on Cancer.
Cervical cancer is a type of cancer that develops in a woman's cervix (the entrance to the womb from the vagina).
Cancer of the cervix often has no symptoms in its early stages. If you do have symptoms, the most common is unusual vaginal bleeding, which can occur after sex, in between periods or after the menopause.
1. 1
CERVICAL CANCER & ITSCERVICAL CANCER & ITS
PREVENTIONPREVENTION
WELCOME!!!!!!!WELCOME!!!!!!!
Educational Program 2016 GMC -CME 1
DR ABDULCADIR M GIAMADR ABDULCADIR M GIAMA
THE EXECUTIVETHE EXECUTIVE
DIRECTOR &DIRECTOR &
PRESIDENT,GLOBALPRESIDENT,GLOBAL
SCIENCE UNIVERSITYSCIENCE UNIVERSITY
DRDR
OSBORNENYANDIVAOSBORNENYANDIVA
Ph.D-CndPh.D-Cnd
THE CONSULTANTTHE CONSULTANT
PATHOLOGISTPATHOLOGIST
2. 2
Sad but True…Sad but True…
In Somalia, 50 womenIn Somalia, 50 women
die each day due todie each day due to
Cervical cancerCervical cancer
4. 4
For you & your daughter …..aFor you & your daughter …..a
wonderful giftwonderful gift
Guard Yourself meansGuard Yourself means
Protect yourselfProtect yourself
very special programmevery special programme
to prevent cervical cancer.to prevent cervical cancer.
5. 5
where is cervix in woman?where is cervix in woman?
Educational Program 2015 5
CERVIX
6. 6
What is cancer?What is cancer?
• Uncontrolled growth of abnormal cells inUncontrolled growth of abnormal cells in
any part of the body.any part of the body.
• Generally due toGenerally due to
1. chemicals (e.g. From smoking )1. chemicals (e.g. From smoking )
2. radiation2. radiation
3. micro-organisms (e.g. Bacteria, viruses)3. micro-organisms (e.g. Bacteria, viruses)
7. 7
Somalia ~10,200
World ~ 4,93,000
Somalia ~27% of new
Cervical Cancer cases in world
Somalia ~ 4,000
World ~ 2,73,000
Somalia ~27%
Rest of World - 73%
Somalia ~27% of deaths
due to Cervical Cancer in world
Rest of World - 73%
India - 27%
Cervical Cancer – Disease Burden
New Cervical Cancer Cases Deaths due to Cervical cancer
Somalia ~27%
Rest of World - 73%
8. 8
Incidence ( Women of all ages) – CervicalIncidence ( Women of all ages) – Cervical
Cancer vs. other CancersCancer vs. other Cancers
2. X. Castellsagué, S. de Sanjose, T. Aguado, K. S. Louie, L. Bruni, J.Muñoz, M. Diaz, K. Irwin, M. Gacic, O. Beauvais, G. Albero, E. Ferrer, S. Byrne, F. X. Bosch. HPV and
Cervical Cancer in the World. 2007 Report. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Available at: www.who.int/hpvcentre
9. 9
HPV 16
HPV 18
HPV 6
HPV 11
Cancer causing Types1,2,4 Non-cancer causing types1,2
• >75% of Cervical Cancer5
• >50% of Vaginal & Vulvar Cancer5
90% of Anogenital warts5
HPV is a necessary cause of cervical cancer – 99.7%4
HPV
1.Schiffman M, Castle PE. Arch Pathol Lab Med. 2003;127:930–934. 2. Wiley DJ, Douglas J, Beutner K, et al. Clin Infect Dis. 2002;35(suppl 2):S210–S224. 3. Muñoz N, Bosch FX, Castellsagué X, et al. Int J
Cancer. 2004;111:278–285. Reprinted from J Virol. 1994;68:4503–4505 with permission from the American Society for Microbiology Journals Department. 4. Walboomers JM, Jacobs MV, Manos MM, et al. J
Pathol. 1999;189:12–19. 5. X. Castellsagué, S. de Sanjose, T. Aguado, K. S. Louie, L. Bruni, J.Muñoz, M. Diaz, K. Irwin, M. Gacic, O. Beauvais, G. Albero, E. Ferrer, S. Byrne,F. X. Bosch. HPV and Cervical
Cancer in the World. 2007 Report. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Available at: www.who.int/hpvcentre
Human Papillomavirus (HPV)
13. Long term use of Hormonal Contraceptive
-> 5-9yrs :: 3 times Risk
-> 10yrs or more :: 4 times Risk
High Parity :: 4 times Risk
Early initiation of Sexual Activity
Multiple Sex PartnersTobacco Smoking (Both active & passive)
HIV Infection
Other STI’s
->Chlamydia Trachomatis
-> HSV 2
Immune Suppression
Low S/E status ; Diet poor in anti oxidants
16. 16
CIN (CERVICAL INTRAEPITHELIAL NEOPLASIA)CIN (CERVICAL INTRAEPITHELIAL NEOPLASIA)
as Seen in Colposcopyas Seen in Colposcopy
CIN 1 CIN 2 CIN 3
Photo courtesy of Dr. Njue Photo courtesy of Dr. Njue Dr.Njue
Colposcopy findings confirmed by histologyColposcopy findings confirmed by histology11
17. 17
How HPV infection can occur?How HPV infection can occur?
Through sexual intercourseThrough sexual intercourse,, verticalvertical
transmission i.e. mother to childtransmission i.e. mother to child &&
fomites.fomites.
It is found that inIt is found that in every 10 women 8every 10 women 8
women might have HPV infectionwomen might have HPV infection atat
anytime in life.*anytime in life.*
Educational Program 2009 17
18. 18
Beware of this symptomsBeware of this symptoms
Consult your doctor immediately if you haveConsult your doctor immediately if you have
• Continuous vaginal discharge,inspite of treatmentContinuous vaginal discharge,inspite of treatment
• Foul smelling, thick discharge,Foul smelling, thick discharge,
• Repeated vaginitis and UTIRepeated vaginitis and UTI
• Post coital bleeding(bleeding after sex)Post coital bleeding(bleeding after sex)
• Non healing or recurrent cervical erosionNon healing or recurrent cervical erosion
• Irregular or intermenstrual bleeding specially in preIrregular or intermenstrual bleeding specially in pre
menopausal phasemenopausal phase
19. 19
Cervical cancer screeningCervical cancer screening
• Chronic painChronic pain
• distensiondistension
• loss of weightloss of weight
• Heavy prolong bleeding ,before or duringHeavy prolong bleeding ,before or during
menopausal agemenopausal age
• Post menopausal bleeding-importantPost menopausal bleeding-important
• Cervical polypCervical polyp
• tumor during or before menopause agetumor during or before menopause age
21. Cervical Cancer is now a virtually preventable disease due to
Early Vaccination
Screening strategies
Long natural history
Cervix is easily accessible
23. 23
What is the use of screeningWhat is the use of screening
program?program?
• Secondary prevention or screeningSecondary prevention or screening
program are helpful in detecting cancerprogram are helpful in detecting cancer
at the early stage hence useful in savingat the early stage hence useful in saving
lives.lives.
26. Population WHO ACS/ASCCP/ASCP
Older than 65
years
Recommends against screening
women who have had adequate prior
screening and are not otherwise at
high risk for cervical cancer.
Grade: D recommendation.
Women with evidence of adequate negative prior
screening and no history of CIN2+ within the last 20
years should not be screened. Screening should not
be resumed for any reason, even if a woman reports
having a new sexual partner.
After
hysterectomy
Recommends against screening in
women who have had a
hysterectomy with removal of the
cervix and who do not have a history
of a high-grade precancerous lesion
(i.e. CIN 2 or 3) or cervical cancer.
Grade: D recommendation
Women of any age following a hysterectomy with
removal of the cervix who have no history of CIN2+
should not be screened for vaginal cancer. Evidence
of adequate negative prior screening is not required.
Screening should not be resumed for any reason,
including if a woman reports having a new sexual
partner.
HPV
vaccinated
Women who have been vaccinated
should continue to be screened
Recommended screening practices should not change
on the basis of HPV vaccination status.
27. PAP Smear
PAP smear sampling of cervix involves scraping of
cervical surface and a portion of non visualised
cervical canal using various sampling devices
28. 28
disasters “disasters “prevention is better than cureprevention is better than cure’-’-
holds true for cervical cancerholds true for cervical cancer
This can be achieved by regular healthThis can be achieved by regular health
check up and regular pap smear testcheck up and regular pap smear test
Pap- smear is cancer screening which isPap- smear is cancer screening which is
easy ,painless and reliable method in whicheasy ,painless and reliable method in which
the discharge from vagina is taken on slidethe discharge from vagina is taken on slide
and sent for examination for presence ofand sent for examination for presence of
abnormal cellsabnormal cells
Routine pap smear has reduced ca cx by 75%Routine pap smear has reduced ca cx by 75%
in developed worldin developed world
Repeat pap is advised if it shows abnormalRepeat pap is advised if it shows abnormal
cells & than advised colposcopy & biopsy.cells & than advised colposcopy & biopsy.
It can give early diagnosis of cancer before itsIt can give early diagnosis of cancer before its
sets in and hence early treatment can avoidsets in and hence early treatment can avoid
diseasedisease
29. Significance of Pap smear
Detect precancerous & invasive cancer cervix cases in
early stages
Positive screeners can be selected for selective tests and
management
With treatment, progression of disease is halted. Thus
morbidity associated with advanced cancer decreases
Mortality reduces by 20-60 %.
Helps us to study natural history of disease.
30. Transformation zone
Cervix develops from 2 embryonic sites
* from Mullerian duct - lined by columnar epithelium
* from urogenital plate - lined by stratified
squamous epithelium
Point at which columnar and squamous epithelium
meet is called as original squamo-columnar
junction
31. Transformation
zone
Under influence of estrogen, original SCJ moves
onto the portio.
Exposure of delicate columnar cells to vaginal
environment leads to squamous metaplasia.
Transformation zone -
- Area of squamous metaplasia
- Area between original and new SCJ
33. Transformation Zone -TZ
Exposure of TZ to carcinogens begins the process of
intraepithelial neoplasia
While exact role of carcinogens in this process remains poorly
understood, it is clear that HPV and cigarette smoking can
cause dysplasia at the TZ
95% of cervical cancers develop in TZ
Important to take sample from TZ
34. 34
PAP SMEARPAP SMEAR
• The cells are taken from the cervix region byThe cells are taken from the cervix region by
speculum & spatula, then smear is preparedspeculum & spatula, then smear is prepared
which is then observed under microscope.which is then observed under microscope.
• It is not recommended in virgin females.It is not recommended in virgin females.
• Recommended in every 3 years to all femaleRecommended in every 3 years to all female
aged more than 30 years.aged more than 30 years.
35. How to take a Pap Smear ?
Spatula is rotated through 360 degrees
maintaining contact with ectocervix
Do not use too much force [bleeding /pain]
Do not use too less force [inadequate sample]
Sample is smeared evenly on the slide and fixed
immediately
Both sides of spatula are to be smeared
36. How to take a Pap Smear ?
Endocervical sample is collected using an
endocervical brush
Insert the cytobrush into canal, so that last bristles
of brush are visible
Rotate the brush through 180 degrees. [more
rotations increase the chance of bleeding]
Sample is rolled on the slide and fixed.
37. Fixation of smear
Fixation is done immediately with
fixative like 95% alcohol or cytofix
spray to avoid air drying
Spray should be kept at 10 inches, to
avoid destruction of cells by
propellent in the spray
Smear should monolayer for proper
penetration of cell surface by fixative
38. Fixation of smear
Fixation is done immediately with
fixative like 95% alcohol or cytofix
spray to avoid air drying
Spray should be kept at 10 inches, to
avoid destruction of cells by
propellent in the spray
Smear should monolayer for proper
penetration of cell surface by fixative
39. Several slides can be prepared from one smearSeveral slides can be prepared from one smear
Chlamydia, HPV testing can be done at later dateChlamydia, HPV testing can be done at later date
Reduces the incidence of inadequate and repeat smearsReduces the incidence of inadequate and repeat smears
Liquid Based Cytology
40. The HPV test is a very accurate way to tell if high-risk HPV is present in a
woman’s cervix.
This test can use the same sample of cells taken for the Pap test.
A positive test result means a woman has high-risk HPV.
A positive HPV test does not mean that a woman has
cancer.
A positive HPV test does not mean that a woman has
cancer.
41. To see if a woman with a borderline Pap test result
(one that shows unusual cells but not dysplasia)
needs additional tests.
To screen for cervical cancer, along with the Pap
test, in women aged 30 or older.
42.
43. 43
COLPOSCOPYCOLPOSCOPY
Colposcopy is the examination of the cervix &Colposcopy is the examination of the cervix &
vagina with a light magnifying instrumentvagina with a light magnifying instrument
colposcope after the application of a vinegarcolposcope after the application of a vinegar
(acetic acid) to the cervix.(acetic acid) to the cervix.
44. ColposcopyColposcopy
• Magnified visual examination of uterine cervix by a lowMagnified visual examination of uterine cervix by a low
power ,stereoscopic microscope with a powerful lightpower ,stereoscopic microscope with a powerful light
source to help in diagnosis of cervical neoplasia .source to help in diagnosis of cervical neoplasia .
• Key ingradients –observations of features of cervicalKey ingradients –observations of features of cervical
epithelium after application of normal saline , 3-5% diluteepithelium after application of normal saline , 3-5% dilute
acetic acid and Lugol’s iodine solution .acetic acid and Lugol’s iodine solution .
•
45. INDICATIONS OF COLPOSCOPYINDICATIONS OF COLPOSCOPY
• Squamous or glandular cell abnormalitiesSquamous or glandular cell abnormalities
• Persistence of inflammatory cells despite adequate ttPersistence of inflammatory cells despite adequate tt
• Presence of keratinized cells .Presence of keratinized cells .
• VIA +ve and VILLI+veVIA +ve and VILLI+ve
• Evaluation of HPV +ve women .Evaluation of HPV +ve women .
• Postcoital ,postmenopausal bleeding .Postcoital ,postmenopausal bleeding .
• Unhealthy cervix .Unhealthy cervix .
• Treatment and monitoring of women with CINTreatment and monitoring of women with CIN
• Anogenital condylomas ,VIN and VAIN.Anogenital condylomas ,VIN and VAIN.
• DES exposure in utero.DES exposure in utero.
46. Colposcopy - ObjectivesColposcopy - Objectives
Determines the presence of invasive cancerDetermines the presence of invasive cancer
Localizes the squamocolumnar junctionLocalizes the squamocolumnar junction
Identifies the most severe disease for biopsyIdentifies the most severe disease for biopsy
Evaluates the extent of diseaseEvaluates the extent of disease
47. A method of identifying
outer & inner borders of the transformation zone
48.
49. Post Menopausal Cervix:
Epithelium is pale, brittle, lacks lusture,
shows sub-epithelial petichiae, SCJ not
visualized
The entire new SCJ is visible
colposcopic examination is satisfactory.
the TZ is fully visualized. The metaplastic
squamous epithelium is pinkish-white
compared to the pink original squamous
epithelium
50. Squamous metaplasia
Earliest colposcopic changes in
immature squamous metaplasia
(after 5% AA) in which tips of
columnar villi stain white &
adjacent villi start fusing together
Prominent white line corresponds to
the new SCJ & tongues of immature
Squamous metaplasia a) with crypt
openings at 4-8 o’clock positions
b) after application of AA
51. Immature squamous metaplastic epithelium (narrow arrow)
on the polyp with intervening areas of columnar epithelium
a) after application of AA
The endocervical polyp &
the immature squamous metaplasia
surrounding the os partially take up
iodine.
52. Immature squamous metaplastic epithelium (narrow arrow)
on the polyp with intervening areas of columnar epithelium
a) after application of AA
The endocervical polyp &
the immature squamous metaplasia
surrounding the os partially take up
iodine.
53. LeukoplakiaLeukoplakia
Usually benignUsually benign
May obscure an underlyingMay obscure an underlying
neoplasianeoplasia
Therefore, all patchesTherefore, all patches
observed before application ofobserved before application of
acetic acid must be biopsiedacetic acid must be biopsied
Hyperkeratosis ( Leukoplakia)
54. 54
CIN (CERVICAL INTRAEPITHELIAL NEOPLASIA)CIN (CERVICAL INTRAEPITHELIAL NEOPLASIA)
as Seen in Colposcopyas Seen in Colposcopy
CIN 1 CIN 2 CIN 3
Photo courtesy of Dr. Njue Photo courtesy of Dr. Njue From ASCP
Colposcopy findings confirmed by histologyColposcopy findings confirmed by histology11
58. Moderately dense acetowhite lesions with well
defined margins & coarse punctations in the
anterior lip & in 3 o’clock position (CIN 2 lesion
Dense well defined acetowhite
area with regular margins &
coarse mosaic ( CIN 2 lesion )
59. A dense acetowhite lesion with varying colour
intensity &
coarse mosaics (a) in a CIN 2 lesion
Acetowhite lesions with coarse punctation
(a) & mosaics (b) in a CIN 2 lesion
60. A circumoral dense opaque acetowhite area with
coarse mosaics ( CIN 3 lesion)
A dense acetowhite lesion with regular
margin & coarse,
irregular punctation in a CIN 3 lesion.
62. Early invasive cancer: note the raised irregular mosaics with umbilication (a), breaking
mosaics (b), surface irregularity & the atypical vessels after the application of 5% AA
Preclinical invasive
Carcinoma
63. Reddish “angry-looking”, inflamed columnar
epithelium with loss of the
villous structure & with inflammatory exudate
(before application of 5% AA)
Inflammatory lesions of the
Uterine Cervix
Chronic cervicitis: This cervix is
extensively inflammed with a reddish
appearance &
bleeding on touch, there are ill-
defined, patchy acetowhite areas
scattered all over the cervix after the
application of AA
64. TV after Acetic acid
T.V. After Lugol’s
Multiple red spots (a) suggestive of Trichomonas
vaginalis colpitis ( strawberry appearance), after
application of 5% AA
Trichomonas vaginalis colpitis
after application of Lugol’s iodine
(leopard-skin appearance)
66. 66
HPV Vaccines- made byHPV Vaccines- made by
recombinant DNA technologyrecombinant DNA technology
67. 67
INDICATIONINDICATION
FOR GardasilFOR Gardasil
For the prevention ofFor the prevention of
Cervical CancerCervical Cancer
Vulvar/ Vaginal PrecancersVulvar/ Vaginal Precancers
Cervical DysplasiaCervical Dysplasia
Genital WartsGenital Warts
Cerverix is only indicated forCerverix is only indicated for
Cervical cancerCervical cancer
69. 69
When we can give this vaccine?When we can give this vaccine?
This vaccine can be given to anyThis vaccine can be given to any
girl above 9 years. Recommendedgirl above 9 years. Recommended
for women of 9-45 years age groupfor women of 9-45 years age group
TheThe most effective timemost effective time toto
vaccinate girls and young womenvaccinate girls and young women
is before they become sexuallyis before they become sexually
activeactive..
Educational Program 2009 69
70. 70
HowHow many dose recommended?many dose recommended?
Three dosesThree doses
First .(as elected date)First .(as elected date)
Second (after 2 month of first dose)Second (after 2 month of first dose)
Third (after 6 month of first dose)Third (after 6 month of first dose)
Cerverix – 0,1 & 6Cerverix – 0,1 & 6
Educational Program 2009 70
6
months
2
Months0
71. 71
Side effectsSide effects
• HPV Vaccines demonstrated a favorable safety profile.HPV Vaccines demonstrated a favorable safety profile.
• Following injection-site reactions occurred at a greaterFollowing injection-site reactions occurred at a greater
incidence in the group that received VACCINEincidence in the group that received VACCINE
– Very common:Very common: erythema, pain, and swellingerythema, pain, and swelling..
– Common:Common: pruritispruritis..
– Most injection-site reactions were mild to moderate.Most injection-site reactions were mild to moderate.
– Very Common (≥1/10); Common (≥1/100, <1/10); Uncommon (≥1/1,000, <1/100); RareVery Common (≥1/10); Common (≥1/100, <1/10); Uncommon (≥1/1,000, <1/100); Rare
(≥1/10,000, <1/1,000); Very Rare (<1/10,000)(≥1/10,000, <1/1,000); Very Rare (<1/10,000)
Educational Program 2009 71
72. 72
Special PopulationSpecial Population
PREGNANT WOMENPREGNANT WOMEN
Because of insufficient trial there is noBecause of insufficient trial there is no
recommendation of this vaccine inrecommendation of this vaccine in
pregnancy.pregnancy.
If woman gets pregnant after first dose ,thenIf woman gets pregnant after first dose ,then
remaining dose should be taken afterremaining dose should be taken after
deliverydelivery..
LACTATING MOTHERLACTATING MOTHER
Lactating woman can take this vaccine.Lactating woman can take this vaccine.
Cerverix is not indicated during lactationCerverix is not indicated during lactation
Educational Program 2015 72
73. 73
Is vaccine costly?Is vaccine costly?
No, if we can see the mortalityNo, if we can see the mortality
rate of the cervical cancer or itsrate of the cervical cancer or its
treatment ,vaccine cost istreatment ,vaccine cost is
nothing against it.nothing against it.
If we see the modern life style ofIf we see the modern life style of
people ,vaccine cost is nothing.people ,vaccine cost is nothing.
People give lacks of rupees ofPeople give lacks of rupees of
dowry to their daughters ,vaccinedowry to their daughters ,vaccine
cost is nothing against it.cost is nothing against it.
It is cost effectiveIt is cost effective
Educational Program 2009
73
74. 74
Screening & Vaccination
Pap testing and screening for HPV DNA or HPVPap testing and screening for HPV DNA or HPV
antibody are not needed before vaccination at any age.antibody are not needed before vaccination at any age.
• Benefits may be limited to protection against HPVBenefits may be limited to protection against HPV
genotypes with which they have not been infected.genotypes with which they have not been infected.
• Women infected with vaccine HPV-type and haveWomen infected with vaccine HPV-type and have
cleared the cervical infection appears to havecleared the cervical infection appears to have
similar protective effects as in HPV naïve to thesimilar protective effects as in HPV naïve to the
same vaccine HPV-type.same vaccine HPV-type.
75. 75
3
North America:
USA
Canada
Mexico
8
South America:
Brazil Bolivia
Argentina Uruguay
Peru Ecuador
Colombia Chile 26
Middle East & Africa:
Gabon Congo Kinshasa
Israel C.A.R.
Morocco Mauritius
Kenya Kuwait
Mauritania UAE
Guinea Eq. Ethiopia
Uganda Togo
Malawi Congo Brazzaville
Jordan Egypt
Cote d’Ivoire Burkina Faso
Chad Bahrain
Saudi Arabia Botswana
South Africa Cameroon
13
Asia Pacific:
Australia
Indonesia
Korea
Taiwan
Hong Kong
Singapore
New Zealand
Macau
Malaysia
Philippines
Thailand
India
Vietnam
40
Europe:
Germany Cyprus Ireland
France Czech Republic Latvia
UK Denmark Lithuania
Spain Estonia Luxembourg
Italy Finland Malta
Austria Greece Netherlands
Belgium Hungary Norway
Bulgaria Iceland Poland
Portugal Romania Slovakia
Slovenia Sweden Serbia
Montenegro Switzerland Liechtenstein
Turkey Croatia Bosnia
Russia Macedonia Belarus
Georgia
Caribbean & Central America:
Costa Rica Trinidad
Puerto Rico El Salvador
Guatemala Honduras
Curaçao Nicaragua
Bermuda Panama
Bahamas Cayman Islands
Barbados Aruba
Jamaica Dominican Republic
16
Gardasil Approvals: 156 countriesGardasil Approvals: 156 countries
76. 76
Is this vaccine is using with anotherIs this vaccine is using with another
developing country?developing country?
Yes, this vaccine is available in 156 country.Yes, this vaccine is available in 156 country.
till date 200 million doses already usedtill date 200 million doses already used
within 9 years of time.within 9 years of time.
Educational Program 2009 76
79. 79
Preventing aspects-lifestyle changePreventing aspects-lifestyle change
Social change –avoid early marriagesSocial change –avoid early marriages
Multiparity_ role of family planningMultiparity_ role of family planning
Avoid multiple partnersAvoid multiple partners
Use of condom to avoid STD,and HPV diseasesUse of condom to avoid STD,and HPV diseases
Improve nutrition and personal hygieneImprove nutrition and personal hygiene
Prevents smoking ,alcoholism ,etcPrevents smoking ,alcoholism ,etc
Regular exerciseRegular exercise
Health awareness-health check upHealth awareness-health check up
80. To produce a Cancer Free Society
Screening and identification of High Risk groups
Education – Think of Cervical Cancer as an
extension of STD
Behavioral changes
Limit number of sexual partners
Delay initial age of sexual intercourse
Avoid STD – Use of Condoms/ Spermicidals;
Avoid Smoking
HPV Vaccines to be promoted at the right age
81. 81
Lets fight against cancerLets fight against cancer
……..join hands……..join hands……
……..take preventive measures……...take preventive measures…….
……..update yourself…....update yourself…..
……..take care…....take care…..
India’s population is approximately 1/6th of the world burden but the disease burden in India is more than 25%( 1/4th)
Key Point
Incidence of cervical cancer cases in India is highest as compared to other cancers in women 15-44 yrs of age
Reference
1) WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Summary report on HPV and cervical cancer statistics in India. 2007. [Accessed on 18th March 2008. Available at www. who. int/ hpvcentre c WHO/ICO Information Centre on HPV and Cervical Cancer
Key Point
Well-demarcated, dense, opaque, acetowhite areas in the transformation zone of the cervix often determine the colposcopic diagnosis of CIN.
Background
The characteristics of acetowhite changes, if any, on the cervix, following the application of dilute acetic acid, are useful in colposcopic interpretation. Acetic acid (3–5%) is applied on the cervix, which helps in both coagulating (precipitation of the nuclear proteins and cytokeratins) and clearing the mucus. When acetic acid is applied to normal squamous epithelium, little coagulation occurs in the superficial cell layer, as this is sparsely nucleated; whereas areas of CIN undergo maximal coagulation due to their higher content of nuclear protein. As a result, in CIN, the epithelium appears white. This reaction is termed acetowhitening, and produces a noticeable effect, compared with the normal pinkish color of normal cervical squamous epithelium.1
Low-grade CIN is often seen as thin, smooth acetowhite lesions with well-demarcated, but irregular, feathery or digitating or angular margins. In comparison to high-grade lesions, many low-grade CIN lesions show mildly dense, less extensive and less complex acetowhite areas close to or abutting the squamocolumnar junction.1
High-grade lesions show well demarcated, regular margins, which sometimes have raised and rolled-out edges. High-grade lesions, like the CIN 2 and CIN 3 examples shown, have a thick, dull, opaque or greyish-white appearance. Course punctation and mosaics can be observed in CIN 2. High-grade CIN may also sometimes extend into the endocervical canal. As CIN lesions become more severe, their surfaces become less smooth and less reflective of light, as in normal squamous epithelium.1
Reference
1. Sellors JW, Sankaranarayanan R, eds. Colposcopy and Treatment of Cervical Intraepithelial Neoplasia. A Beginner’s Manual. Lyon, France: International Agency for Research on Cancer; 2003.
Key Point
Well-demarcated, dense, opaque, acetowhite areas in the transformation zone of the cervix often determine the colposcopic diagnosis of CIN.
Background
The characteristics of acetowhite changes, if any, on the cervix, following the application of dilute acetic acid, are useful in colposcopic interpretation. Acetic acid (3–5%) is applied on the cervix, which helps in both coagulating (precipitation of the nuclear proteins and cytokeratins) and clearing the mucus. When acetic acid is applied to normal squamous epithelium, little coagulation occurs in the superficial cell layer, as this is sparsely nucleated; whereas areas of CIN undergo maximal coagulation due to their higher content of nuclear protein. As a result, in CIN, the epithelium appears white. This reaction is termed acetowhitening, and produces a noticeable effect, compared with the normal pinkish color of normal cervical squamous epithelium.1
Low-grade CIN is often seen as thin, smooth acetowhite lesions with well-demarcated, but irregular, feathery or digitating or angular margins. In comparison to high-grade lesions, many low-grade CIN lesions show mildly dense, less extensive and less complex acetowhite areas close to or abutting the squamocolumnar junction.1
High-grade lesions show well demarcated, regular margins, which sometimes have raised and rolled-out edges. High-grade lesions, like the CIN 2 and CIN 3 examples shown, have a thick, dull, opaque or greyish-white appearance. Course punctation and mosaics can be observed in CIN 2. High-grade CIN may also sometimes extend into the endocervical canal. As CIN lesions become more severe, their surfaces become less smooth and less reflective of light, as in normal squamous epithelium.1
Reference
1. Sellors JW, Sankaranarayanan R, eds. Colposcopy and Treatment of Cervical Intraepithelial Neoplasia. A Beginner’s Manual. Lyon, France: International Agency for Research on Cancer; 2003.
We want to make it available everywhere
Approval vs. Launch * Note: Due to importation, distribution and other regulatory requirements as well as price negotiations, a licensed vaccine may not be marketed in a given country.
Registration pending in 26 additional GAVI-eligible countries + WHO pre-qualification submitted
Potential Q: which GAVI countries have access to GARDASIL? Indonesia, Kenya and Nicaragua